ASCO 2021: Updates in Lymphoma

ASCO 2021: Updates in Lymphoma

Penpulimab Shows Promise for Relapsed/Refractory Classic Hodgkin Lymphoma

Penpulimab led to an ORR of 89.4% among patients with R/R cHL, with a low rate of SAEs, according to results of a study presented at the 2021 American Society of Clinical Oncology Annual Meeting.

Cancer Therapy Advisor
Romidepsin and Lenalidomide Combination Effective as Initial Therapy for Peripheral T-Cell Lymphoma

The combination of romidepsin and lenalidomide is feasible and effective as initial therapy for patients with PTCL who are not candidates for cytotoxic CT, per research presented at ASCO 2021.

Cancer Therapy Advisor
Adding Bortezomib to Front-Line Induction in Mantle Cell Lymphoma Did Not Extend Progression-Free Survival

According to results of the ECOG-ACRIN E1411 randomized phase 2 trial, the addition of bortezomib to bendamustine-rituximab induction therapy did not significantly improve PFS in patients with MCL.

Cancer Therapy Advisor

Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma

Genentech today announced that new data on mosunetuzumab, glofitamab, and polatuzumab vedotin in NHL are being presented at the 2021 ASCO Annual Meeting.

Genentech Presents Latest Advances With Immunotherapies in Non-Hodgkin’s Lymphoma

Genentech today announced that new data on mosunetuzumab, glofitamab, and polatuzumab vedotin in NHL being presented at the 2021 ASCO Annual Meeting.

ASCO 2021: Recommendations From Dr Noël Milipied for Lymphoma and CLL

Noël Milpied MD, PhD, highlights notable sessions being presented at the ASCO Annual Meeting in the lymphoma space.

Roswell Park Researchers Gear Up for ASCO 2021 Annual Meeting

At the ASCO Annual Meeting, Roswell Park Comprehensive Cancer Center teams will share new data and insights on a variety of topics.

Guangzhou Bio-Gene Announces Oral Presentation at the 2021 ASCO Annual Meeting

Guangzhou Bio-Gene, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies, today announced the company will present at the 2021 ASCO Annual Meeting.

Increased Risk For HZ Varies by Age, Treatment in Patients With CLL

According to study findings being presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.

Oncology Learning Network
Cirmtuzumab, Ibrutinib Therapy Well Tolerated In Both CLL/MCL

Cirmtuzumab when given in combination with ibrutinib is a well-tolerated and active regimen for patients with b-cell lymphoid malignancies, according to study findings presented at the virtual 2021

Oncology Learning Network
Triplet Therapy Shows Promise in Patients With RR FL

Treatment with polatuzumab vedotin, obinutuzumab, and venecolax, shows promise in the response rates at end of induction in patients with RR FL, according to data being presented at the virtual 202

Oncology Learning Network

source list reference

rgb(171, 222, 222)
rgb(219, 18, 118)
200, 66, 245
rgb(195, 2, 230)
rgb (247, 7, 79)
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
rgb(242, 0, 137)
rgb (247, 7, 79)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb (252, 186, 3)
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
rgb(224, 4, 129)
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
rgb (245, 152, 2)
rgb(169, 196, 201)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb (191, 171, 145)
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
rbg(16, 162, 230)
rgb(217, 7, 192)
rgb(224, 224, 4)
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)